Xintela AB (XINT) AI Stock Analysis

• Market Cap: kr199.81M
• Dividend Yield: N/A
• Average Volume (3M): 554.92K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.71
• Revenue Growth: -7.68%
• EPS Growth: 17.93%
• Country: SE
• Employees: 21
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.02
• Shares Outstanding: 861,266,850
• 10 Day Avg. Volume: 503,836
• 30 Day Avg. Volume: 554,918
• PEG Ratio: -1.38
• Price to Book (P/B): -37.15
• Price to Sales (P/S): 85.84
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): -0.11
• Revenue Forecast (FY): N/A

• Rating: 41 Neutral
• Price Target: kr0.21 ▼(-24.64% Downside)
• Action: Reiterated Date: 03/03/26
• Date: Action: Reiterated 03/03/26

The score is primarily constrained by weak financial performance—persistent losses, significant cash burn, and negative equity—indicating high reliance on external funding. Technicals also lean bearish with price below key moving averages and negative MACD, while valuation is not supportive due to negative earnings and no dividend yield.

Positive Factors

Focused R&D target (α10β1)

Xintela’s clear scientific focus on the integrin α10β1 marker creates a durable platform approach across regenerative orthopedics and oncology. A single well‑defined target can concentrate R&D resources, support repurposing across indications, and improve odds of building a differentiated pipeline over the medium term.

Zero debt / low leverage

Having no interest‑bearing debt materially reduces near‑term refinancing and interest‑service risk, giving management flexibility to prioritize R&D investment and partnership strategies. For an early‑stage biotech, this lowers mandatory cash outflows and preserves optionality for licensing or equity financing.

Positive gross profit reported

Recording positive gross profit implies revenue streams can cover direct product or service costs, indicating unit economics that could scale. If fixed operating expenses are controlled and revenues grow, gross margin strengths provide a pathway to improving operating leverage and eventual profitability.

Negative Factors

Persistent heavy cash burn

Sustained negative operating cash flow at material levels depletes runway and raises ongoing capital‑raising needs. This structural cash burn forces frequent dilution or dependency on partners and can constrain long‑term project timelines, R&D continuity, and strategic negotiation leverage with collaborators.

Negative shareholders' equity

A negative equity position weakens balance‑sheet resilience and can signal cumulative losses exceeding capital. It limits financing options, increases perceived risk for partners and lenders, and may create governance or listing pressures that impair the company’s ability to execute long‑term development plans without corrective capital measures.

Loss‑making with volatile, small revenue

The combination of persistent operating losses and volatile, modest revenues indicates commercialization challenges and a cost base misaligned with current income. Revenue declines after prior growth highlight execution risk and unpredictability in cash inflows, complicating forecasting and strategic investment choices.

Xintela AB Business Overview & Revenue Model

Company Description

Xintela AB (publ), a biomedical company, operates in the fields of regenerative medicine and cancer, focusing on cartilage damage and brain tumors. The company develops products based on XINMARK, a patented marker technology that identifies and selects a range of stem cells, which can develop cartilage cells. It is also developing XSTEM a stem cell product that is in clinical development phase for the treatment of knee osteoarthritis and difficult-to-heal leg ulcers; and EQSTEM, a stem cell product for the treatment of joint diseases in horses, as well as focuses on the preclinical development of therapeutic antibodies for aggressive cancers, including brain tumor glioblastoma and triple negative breast cancer. Xintela AB (publ) was founded in 2009 and is based in Lund, Sweden.

How the Company Makes Money

null

Xintela AB Financial Statement Overview

Summary

Financials reflect an early-stage biotech with structurally weak performance: persistent deep operating/net losses, consistently heavy operating cash burn, and negative shareholders’ equity in 2024–2025. Zero debt reduces refinancing risk, but the negative equity and ongoing funding dependence materially increase financial risk.

Income Statement

The company remains firmly loss-making, with EBIT and net income deeply negative across all reported years. Revenue is volatile and still very small relative to the cost base (2025 revenue fell ~23% year over year after strong growth in 2024), which keeps profitability structurally challenged despite positive gross profit in 2024–2025. Overall, the income statement reflects an early-stage biotech profile with limited commercialization traction and persistent operating losses.

Balance Sheet

Leverage is low with total debt at 0 in recent years, reducing refinancing risk. However, shareholders’ equity turned negative in 2024 and remained negative in 2025, which materially weakens balance-sheet resilience and limits financial flexibility. Total assets are relatively stable, but the negative equity position is a key red flag despite the lack of debt.

Cash Flow

Operating cash flow is consistently and heavily negative (roughly -40 to -53M in 2021–2025), indicating ongoing cash burn to fund operations. Free cash flow is also negative when reported, and cash generation does not support the current cost structure, increasing dependency on external financing. While the magnitude of burn fluctuates year to year, there is no clear, sustained trend toward breakeven cash flow.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	2.28M	4.21M	78.00K	0.00	0.00
Gross Profit	1.68M	4.21M	78.00K	-3.79M	-3.50M
EBITDA	-46.08M	-38.90M	-53.47M	-65.28M	-57.11M
Net Income	-48.56M	-39.19M	-54.08M	-66.22M	-58.93M
Balance Sheet
Total Assets	29.02M	24.80M	18.39M	24.52M	24.74M
Cash, Cash Equivalents and Short-Term Investments	23.21M	16.68M	7.81M	8.34M	9.94M
Total Debt	0.00	0.00	0.00	0.00	0.00
Total Liabilities	34.30M	30.75M	14.02M	18.74M	20.80M
Stockholders Equity	-5.27M	-5.95M	4.38M	5.78M	3.95M
Cash Flow
Free Cash Flow	0.00	-40.70M	-53.22M	-39.60M	-44.15M
Operating Cash Flow	-41.62M	-40.70M	-53.12M	-39.49M	-42.89M
Investing Cash Flow	0.00	0.00	-104.00K	-27.52M	-1.20M
Financing Cash Flow	48.53M	50.09M	51.79M	64.56M	20.43M

Xintela AB Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.28
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:XINT, the sentiment is Negative. The current price of 0.28 is above the 20-day moving average (MA) of 0.26, below the 50-day MA of 0.28, and below the 200-day MA of 0.35, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 32.35 is Neutral, neither overbought nor oversold. The STOCH value of 10.46 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:XINT.

Xintela AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ISOFOL	49 Neutral	kr191.15M	-2.92	-51.35%	―	―	-34.02%
ELIC	48 Neutral	kr268.89M	-13.67	-59.78%	―	―	52.96%
ACTI	45 Neutral	kr108.87M	-1.66	-1291.15%	―	―	28.54%
IRLAB.A	43 Neutral	kr135.39M	-1.72	-199.86%	―	69.03%	23.10%
MODTX	43 Neutral	kr32.47M	-1.03	-457.91%	―	―	-19.35%
XINT	41 Neutral	kr199.81M	-4.03	―	―	-7.68%	17.93%